Skip to Content

'
Sue-Hwa Lin, Ph.D.

Present Title & Affiliation

Primary Appointment

Professor of Translational Molecular Pathology, Department of Translational Molecular Pathology, Division of Pathology/Lab Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Dual/Joint/Adjunct Appointment

Professor of Genitourinary Oncology, Department of Genitourinary Oncology, Division of Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Research Interests

The work in our lab focuses on the identification of proteins involved in the metastasis of prostate cancer cells to bone and the progression of prostate cancer in bone. Prostate cancer has a propensity to metastasize to bone and induce blastic bone lesions.  Bi-directional interactions between prostate cancer cells and osteoblasts likely play important roles in the progression of prostate cancer in bone. We have used protein fractionation and proteomics approaches to identify, in bone marrow samples from prostate cancer patients, factors that may play significant roles in the progression of prostate cancer cells in bone.  Several factors have been identified as potential regulators of prostate cancer bone metastasis, and their functional roles in prostate cancer bone metastasis are being investigated.  We are also studying adhesion molecules that mediate the metastasis of prostate cancer cells to bone.  Because these adhesion molecules likely provide a link between the metastatic prostate cancer cells and the bone, our studies may lead to the development of these adhesion molecules as markers for detecting circulating prostate cancer cells that can potentially colonize in bone.  In addition, these studies may lead to new strategies for preventing prostate cancer metastasis to bone.

Office Address

The University of Texas MD Anderson Cancer Center
1515 Holcombe Boulevard
Unit Number: 89
Houston, TX 77030
Room Number: T7.3912
Phone: (713) 794-1559
Fax: (713) 834-6084
Email: slin@mdanderson.org

Education & Training

Degree-Granting Education

1984 Brown University, Providence, RI, PHD, Biology and Medicine
1979 National Taiwan University, Taipei, Taiwan, China, MS, Biochemical Sciences
1977 National Taiwan University, Taipei, Taiwan, China, BS, Pharmaceutical Sciences

Postgraduate Training

9/1983-10/1988 Post-Doctoral Fellow, Department of Biochemistry and Molecular Biology, Harvard University, Cambridge, MA, Dr. Guido Guidotti

Experience/Service

Academic Appointments

Associate Professor, Department of Genitourinary Oncology, Division of Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 1/1995-1/2000
Associate Professor, Department of Molecular Pathology, Division of Pathology and Laboratory Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 1/1994-1/2000
Member of Graduate Faculty, The University of Texas Graduate School of Biomedical Sciences, Houston, TX, 1/1989-present
Assistant Professor, Department of Translational Molecular Pathology, Division of Pathology/Lab Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 1/1988-1/1994
Research Associate, Professor Guido Guidotti's Laboratory, Harvard University, Cambridge, MA, 1/1983-1/1988

Administrative Appointments/Responsibilities

Deputy Chair, Department of Translational Molecular Pathology, Division of Pathology/Lab Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 9/2005-8/2012

Selected Publications

Peer-Reviewed Original Research Articles

1. Ye X, Lee YC, Choueiri M, Chu K, Huang CF, Tsai WW, Kobayashi R, Logothetis CJ, Yu-Lee LY, Lin SH. Aberrant expression of katanin p60 in prostate cancer bone metastasis. Prostate 72(3):291-300, 2/2012. e-Pub 6/2011. PMCID: PMC3179562.
2. Gallick GE, Corn PG, Zurita AJ, Lin SH. Small-molecule protein tyrosine kinase inhibitors for the treatment of metastatic prostate cancer. Future Med Chem 4(1):107-19, 1/2012. PMCID: PMC3285098.
3. Lee YC, Cheng CJ, Bilen MA, Lu JF, Satcher RL, Yu-Lee LY, Gallick GE, Maity SN, Lin SH. BMP4 promotes prostate tumor growth in bone through osteogenesis. Cancer Res 71(15):5194-203, 8/2011. e-Pub 6/2011. PMCID: PMC3148283.
4. Lee Y-C, Cheng C-J, Huang M, Bilen MA, Ye X, Navone NM, Chu K, Kao H-H, Yu-Lee L-y, Wang Z, Lin S-H. Androgen Depletion Upregulates Cadherin-11 Expression in Prostate Cancer. J. Path 221:68-76, 2010.
5. Huang C-F, Lira C, Chu K, Bilen MA, Lee Y-C, Ye X, Kim S-M, Ortiz A, Lin-Wu F-L, Logothetis CJ, Yu-Lee L-Y, Lin S-H. Cadherin-11 increases migration and invasion of prostate cancer cells and enhances their interaction with osteoblasts. Cancer Research 70:4580-4589, 2010.
6. Lee YC, Huang C-F, Murshed M, Chu K, Araujo JC, Ye X, deCrombrugghe B, Yu-Lee L-y, Gallick GE, and Lin S-H. The Src Family Kinase/Abl Inhibitor Dasatinib Suppresses Proliferation and Enhances Differentiation of Osteoblasts. Oncogene 29:3196-3207, 2010.
7. Zhang S, Wang J, Bilen MA, Lin S-H, Stupp S and Satcher RL. Modulation of prostate cancer cell gene expression by cell-to-cell contact with bone marrow stromal cells or osteoblasts. Clinical & Experimental Metastasis 26:993-1004, 2009.
8. Lin S-H, Cheng C-J, Lee Y-C, Tsai W-W, Kim J, Pasqualini R, Arap W, Navone NM, Tu S-M, Hu M, Yu-Lee Y-Y, and Logothetis CJ. A 45-kDa ErbB3 secreted by prostate cancer cells promotes bone formation. Oncogene 27:5195-5203, 2008.
9. Li ZG, Mathew P, Yang J, Starbuck MW, Zurita AJ, Liu J, Sikes C, Multani AS, Efstathiou E, Lopez A, Wang J, Fanning TV, Prieto VG, Kundra V, Vazquez ES, Troncoso P, Raymond AK, Logothetis CJ, Lin S-H, Maity S and Navone NM. Androgen receptor-negative human prostate cancer cells induce osteogenesis in mice through FGF9-mediated mechanisms. J. Clin. Invest. 118(8):2697-2710, 2008.
10. Chu K, Cheng C-J, Ye X, Lee Y-C, Zurita AJ, Chen D-T, Yu-Lee L-Y, Zhang S, Yeh ET, Hu M C-T, Logothetis CJ, Lin S-H. Cadherin-11 promotes the metastasis of prostate cancer cells to bone. Mol Cancer Res 6:1259-1267, 2008.
11. Tu, S-M and Lin, S-H. Current trails using agents that target bone metastatsis in prostate cancer. Cancer J. 14:35-39, 2008.
12. Lin S-H, Lee Y-C, Choueiri MB, Wen S, Mathew P, Ye X-C, Do K-A, Navone NM, Kim J, Tu S-M, Yu-Lee L-Y and Logothetis CJ. Soluble ErbB3 levels in bone marrow and plasma of men with prostate cancer. Clin. Cancer Res. 14:3729-3736, 2008.
13. Logothetis, C.J., Navone, N.M., and Lin, S-H. Understanding the Biology of Bone Metastases: Key to the Effective Treatment of Prostate Cancer. Clinical Cancer Res. 14:1599-1602, 2008.
14. Lee S-H, Kunz J, Lin S-H, Yu-Lee L-Y. 16-kDa prolactin inhibits endothelial cell migration by downregulating the Ras-Tiam1-Rac1-Pak1 signaling pathway. Cancer Research 67:11045-11053, 2007.
15. Chen N, Ye X-C, Chu K, Navone NM, Sage EH, Yu-Lee L-Y, Logothetis C, Lin S-H. A secreted isoform of ErbB3 promotes osteonectin expression in bone and enhances the invasiveness of prostate cancer cells. Cancer Res 67:6544-6548, 2007.
16. Cheng C-J, Ye X-C, Vakar-Lopez F, Kim J, Tu S-M, Chen D-T, Navone NM, Yu-Lee L-Y, Lin S-H, Hu MC. Bone microenvironment and androgen status modulate subcellular localization of ErbB3 in prostate cancer cells. Mol Cancer Res 5:675-684, 2007.
17. Logothetis CJ, Lin SH. Osteoblasts in prostate cancer metastasis to bone. Nat Rev Cancer 5(1):21-8, 2005. PMID: 15630412.

Invited Articles

1. Lin S-H, Guidotti G. Purification and membrane proteins. In Methods in Enzymology. Guide to Protein Purification. Burgess, R. and Deutscher M. Editors 463:619-629, 2009.

Grant & Contract Support

Title: Prostate Cancer Bone Metastasis Secretome
Funding Source: Cancer Prevention & Research Institute of Texas (CPRIT)
Role: Principal Investigator
Duration: 12/1/2010 - 11/30/2013
 
Title: Prostate Cancer Foundation Clinical Research Consortium: Individualized Microenvironment Targeted Therapy for Prostate Cancer Bone Metastases: Rapid Evaluation of Multiple Therapeutic Agents
Funding Source: Prostate Cancer Foundation
Role: Co-Principal Investigator
Principal Investigator: Christopher Logethetis
Duration: 5/1/2010 - 12/31/2012
 
Title: Cadherin-11 as a target for bone metastasis prevention
Funding Source: DOD/Congressionally Directed Medical Research Programs (DOD/CDMRP)
Role: Principal Investigator
Duration: 3/1/2010 - 3/31/2013
 
Title: Career Development Award component, Special Program of Research Excellence (SPORE) in Prostate Cancer
Funding Source: NIH/NCI
Role: Director
Principal Investigator: Christopher Logothetis
Duration: 9/2/2009 - 10/31/2014
 
Title: RSK2 in Prostate Cancer
Funding Source: DOD/Congressionally Directed Medical Research Programs (DOD/CDMRP)
Role: Principal Investigator
Duration: 4/13/2009 - 5/12/2013

Last updated: 8/2/2013